Preparedness is an awkward product. The ideal customer needs it before the need is obvious, the sales cycle can run for years, and a successful outcome may look like a warehouse door that never opens. John McManus has spent much of his working life in that paradox. His business is biotechnology, but his clock is set by public danger: chemical, biological and radiological-nuclear threats, and the complicated work required to have a response ready before any alarm sounds.
Today, Partner Therapeutics lists McManus as President, Health Security. The title is newer than the work. The company says he has spent more than 15 years developing medical countermeasures and has obtained and managed more than $500 million in procurement and development contracts. Those numbers suggest scale. They do not quite explain the job, which lives in the crowded space between laboratory evidence, federal priorities, manufacturing capacity, regulatory rules and events no sensible person would put on a calendar.
A financier walks into a laboratory
McManus did not begin as a scientist. He graduated from the University of Southern California in 1986 with a degree in international finance and business economics. By 1989, he was running McManus Financial Consultants, advising executives and boards on strategy, investor relations, acquisitions and the less romantic arts of making a company add up.
That background became useful in small biotechnology companies, where ambition is usually abundant and cash is not. At Spectrum Pharmaceuticals, he took responsibility for finance and strategic planning. A later Aeolus filing credited the restructuring plan he helped execute with lifting Spectrum's market value from $1 million to more than $125 million by the time he left. Corporate filings are written in the language of attribution and risk, but even in that dialect the plot is plain: he learned how to change the direction of a company without pretending its constraints had vanished.
In June 2005, Aeolus Pharmaceuticals brought him in as president. The announcement described a semi-virtual company intent on spending less on infrastructure and more on its experimental portfolio. McManus became President and Chief Operating Officer in 2006, then chief executive in 2007. The ascent matters less than the assignment. Aeolus was trying to develop AEOL 10150, a compound with potential commercial uses and a second identity as a countermeasure against the effects of radiation and chemical exposure.
“Our commitment to investors is to primarily focus our financial resources on the development and clinical evaluation of promising candidates.”Aeolus management, announcing McManus's arrival in 2005
The contract that changed the scale
In 2011, Aeolus received a Biomedical Advanced Research and Development Authority contract worth up to $118 million. BARDA exists for the peculiar market in which normal commercial incentives can fail: preparing medicines and tools for emergencies that are grave, uncertain and, with luck, rare. The award moved Aeolus from a small drug developer with an interesting candidate into a long partnership with the federal government.
The arrangement also reversed the familiar picture of government standing at the end of a pharmaceutical process with a stamp and a rule book. Here, a public agency helped define the goal, supplied technical expertise and funded work toward it. The prospective buyer was also a development partner. That makes fluency in milestones and contracts nearly as important as fluency in markets. McManus had to explain the science to capital, the capital plan to government and the government's requirements back to a network of researchers. Every translation created another chance for delay, and every completed handoff made the program a little more real.
The company was still tiny. McManus told a local reporter that Aeolus would hire two people after the award, bringing its staff to eight. Research was distributed among institutions including Duke University, the University of Maryland, the University of Colorado and National Jewish Health. Eight employees, several universities, one federal agency and a contract with nine figures make a fine recipe for meetings. They also reveal McManus's practical specialty: arranging other people's expertise so that evidence, money and deadlines travel in roughly the same direction.
Aeolus's path was not tidy. Development programs met clinical and regulatory obstacles, the federal options did not erase financing risk, and in 2017 the company began an assignment for the benefit of creditors. Preparedness does not suspend the laws of small-company finance. If anything, it adds extra clocks. A medicine must progress scientifically while government budgets, public priorities and capital markets keep their own time.
That ending complicates any polished tale of a contract transforming a company. The award was consequential, but it was not a guarantee. Programs can advance while companies strain. Knowledge, relationships and operating habits may outlast the corporate vehicle that assembled them. In McManus's case, they became the basis for the next chapter.
McManus carried that education forward. When Partner Therapeutics hired him as Chief Business Officer in November 2019, his brief covered business development and government relations. Chief executive Bob Mulroy pointed to his experience working with the United States government. McManus spoke about strengthening the company's Leukine franchise, finding products suited to its development capabilities and expanding third-party partnerships.
Partnership as an operating system
Partnership can be a soft word in a corporate biography, the linguistic equivalent of a lobby sofa. In McManus's field it is harder furniture. Partner Therapeutics has worked with the Department of Defense on advanced development, with European biotechnology companies on potential biodefense applications, with academic investigators and with public-health institutions. Each party brings a different vocabulary and a different definition of soon.
McManus's public remarks tend to be verbs in sensible shoes: work, support, advance, expand. He thanked the Defense Department for backing one development program and said the company looked forward to continuing the work. On another collaboration, he emphasized exploring a potential product against future pandemic threats. The repetition is revealing. His career has been less about a single scientific bet than about building a reusable way for companies and governments to make bets together.
“We look forward to working with the JPEO-CBRND and continuing to expand the utility of Leukine as an MCM in areas of interest to the United States Government.”John McManus, 2022
The system was tested in public view in March 2022, as fighting in Ukraine raised concern about nuclear facilities. McManus told CNN that Partner Therapeutics had contacted the World Health Organization to offer its product on a humanitarian basis if it was needed. “There is a small window to treat people after a nuclear event,” he said. Outreach, in that circumstance, meant awareness and preparation rather than a conventional sales pitch.
The moment condensed years of work into a few uncomfortable questions. Was supply available? Which institution could receive an offer? What authority would guide use? Could a product move across borders in time? A countermeasure sitting in a catalogue is an object. A countermeasure connected to decision-makers, transport, instructions and trained teams is preparedness. McManus has built a career in the difference.
A career measured before the emergency
His title at Partner Therapeutics has since changed from Chief Business Officer to President, Health Security. The promotion gives a name to the through-line. Finance taught him to allocate scarce resources. Consulting taught him to speak to boards and investors. Aeolus taught him the long mechanics of federally supported development. Partner Therapeutics gave those experiences a larger portfolio and a clearer institutional home.
He continues to appear in the technical conversation, too. A 2025 radiation-preparedness conference listed McManus as a coauthor with Yale professor Nicholas Dainiak on work involving radiation exposure, sepsis and military space operations. He was also credited on earlier conference material concerning the wider use of an approved product as a countermeasure. He is not presented as the laboratory scientist. His role is the connective one: keeping the science in conversation with the institutions that might develop, approve and deploy it.
There is an old business fantasy that every important achievement announces itself with a bell. Preparedness offers fewer bells. A contract is signed. A study proceeds. A manufacturing plan is checked, revised and checked again. Partners agree on the next milestone. Years may pass before the public learns the product exists, usually on a day when it would have preferred not to know.
McManus has chosen work in that long prelude. The $500 million figure is impressive, but the more interesting accomplishment is temporal: persuading people and institutions to act while danger remains conditional. It is a job for someone who can value patience without confusing it for delay. When the business succeeds, a country owns an option it may never exercise. Few products come with a happier definition of waste.